secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-006992
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin achieves positive cash flow in Q4 2025 ahead of schedule; FY revenue $212-217M
--------------------------------------------------------------------------------

- Year-end cash $303M, up $16M from Q3; no debt; Q4 positive cash flow achieved earlier than forecast.
- Q4 2025 net revenue expected $48-53M; FY 2025 net revenue $212-217M.
- Restructuring: 50% of $70M OPEX savings realized; full benefit on track by June 30, 2026. Estimated restructuring costs raised to $37-40M.
- VASCEPA >50% IPE prescription share in US; Recordati now managing European commercialization in most launched countries.
- Two new regulatory approvals (South Korea and Singapore); >10 abstracts and >20 manuscripts published in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000119312526006992/0001193125-26-006992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000119312526006992/amrn-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer